Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA).
Saved in:
| Title: | Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA). |
|---|---|
| Authors: | Prins HAB; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands., Zino L; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Leena.zino@radboudumc.nl., Svensson EM; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands; Uppsala University, Department of Pharmacy, Uppsala, Sweden., Verbon A; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands., de Bree GJ; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands., Prins JM; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands., Reiss P; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam University Medical Centre, University of Amsterdam, Department of Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands., Burger DM; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands., Rokx C; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands., Colbers A; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands. |
| Corporate Authors: | NOVA Study Team |
| Source: | International journal of antimicrobial agents [Int J Antimicrob Agents] 2023 Jan; Vol. 61 (1), pp. 106697. Date of Electronic Publication: 2022 Dec 02. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Elsevier Science Publishers Country of Publication: Netherlands NLM ID: 9111860 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1872-7913 (Electronic) Linking ISSN: 09248579 NLM ISO Abbreviation: Int J Antimicrob Agents Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 36470510 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA). – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Prins+HAB%22">Prins HAB</searchLink>; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Zino+L%22">Zino L</searchLink>; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands. Electronic address: Leena.zino@radboudumc.nl.<br /><searchLink fieldCode="AU" term="%22Svensson+EM%22">Svensson EM</searchLink>; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands; Uppsala University, Department of Pharmacy, Uppsala, Sweden.<br /><searchLink fieldCode="AU" term="%22Verbon+A%22">Verbon A</searchLink>; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22de+Bree+GJ%22">de Bree GJ</searchLink>; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Prins+JM%22">Prins JM</searchLink>; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Reiss+P%22">Reiss P</searchLink>; Amsterdam University Medical Centre, University of Amsterdam, Department of Internal Medicine, Division of Infectious Diseases, and Amsterdam Institute for Infection and Immunity, Amsterdam, The Netherlands; Amsterdam University Medical Centre, University of Amsterdam, Department of Global Health, and Amsterdam Institute for Global Health and Development, Amsterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Burger+DM%22">Burger DM</searchLink>; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Rokx+C%22">Rokx C</searchLink>; Erasmus Medical Centre, Department of Medical Microbiology and Infectious Diseases and Department of Internal Medicine, Rotterdam, The Netherlands.<br /><searchLink fieldCode="AU" term="%22Colbers+A%22">Colbers A</searchLink>; Radboud University Medical Centre, Department of Pharmacy and Radboud Institute for Health Sciences, Nijmegen, The Netherlands. – Name: AuthorCorporate Label: Corporate Authors Group: Au Data: <searchLink fieldCode="CA" term="%22NOVA+Study+Team%22">NOVA Study Team</searchLink> – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%229111860%22">International journal of antimicrobial agents</searchLink> [Int J Antimicrob Agents] 2023 Jan; Vol. 61 (1), pp. 106697. <i>Date of Electronic Publication: </i>2022 Dec 02. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Elsevier+Science+Publishers%22">Elsevier Science Publishers </searchLink><i>Country of Publication: </i>Netherlands <i>NLM ID: </i>9111860 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1872-7913 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2209248579%22">09248579 </searchLink><i>NLM ISO Abbreviation: </i>Int J Antimicrob Agents <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=36470510 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1016/j.ijantimicag.2022.106697 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 106697 Titles: – TitleFull: Exposure and virologic outcomes of dolutegravir combined with ritonavir boosted darunavir in treatment-naïve individuals enrolled in the Netherlands Cohort Study on Acute HIV infection (NOVA). Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Prins HAB – PersonEntity: Name: NameFull: Zino L – PersonEntity: Name: NameFull: Svensson EM – PersonEntity: Name: NameFull: Verbon A – PersonEntity: Name: NameFull: de Bree GJ – PersonEntity: Name: NameFull: Prins JM – PersonEntity: Name: NameFull: Reiss P – PersonEntity: Name: NameFull: Burger DM – PersonEntity: Name: NameFull: Rokx C – PersonEntity: Name: NameFull: Colbers A IsPartOfRelationships: – BibEntity: Dates: – D: 01 M: 01 Text: 2023 Jan Type: published Y: 2023 Identifiers: – Type: issn-electronic Value: 1872-7913 Numbering: – Type: volume Value: 61 – Type: issue Value: 1 Titles: – TitleFull: International journal of antimicrobial agents Type: main |
| ResultId | 1 |
